



[REDACTED]

5 February 2021

Dear [REDACTED]

Freedom of Information request: FOI2021/00012

Thank you for your Freedom of Information request received on the 13 January in which you requested the following:

Your request:

Please provide answers to the following questions:

1. *How much money has been spent by Innovate UK on cell and gene therapy catapult?*
2. *How much money has been spent on technology and digitisation? Alternatively, what have been the main areas of expenditure? What was the output of this spending?*
To clarify the question, how much funding was provided by Innovate UK to Cell and Gene Therapy annually since inception.
3. *How much money was given to commercial technology partners of cell and gene therapy catapult? Who are the commercial partners, what was their function, and what technology or digital solution or services were provided and how did it help the sector?*
4. *How much money was spent with World Courier, DHL, ThermoFisher, Trakcel, Oxford Biomedica, and GSK? What was the purpose of the money and what was the result or outcome of such funding? What digital product and transformation was the result of such funding?*
To clarify the question, how much money has Cell and Gene Therapy Catapult provided to commercial partners annually, what was the money provided for and with which commercial partner, what products, solutions or outcomes was the funding for, and what specific identifiable outcomes, products or solutions were built or produced as a result of the funding provided to such commercial partners.
5. *How many NHS hospitals, clinics or manufacturers in the UK or overseas are utilising innovations in technology produced by Trakcel or World Courier, and how much in funding was provided to these companies?*
To clarify the question, where, when or with which other entities, are any of the commercial partners' products or solutions being used?

Our response

I can confirm UK Research and Innovation (UKRI) hold some of the information relevant to your request. Please see the information below.

1. How much money has been spent by Innovate UK on cell and gene therapy catapult?

Under Section 21 - Information already reasonably accessible, of the FOIA the information you have requested is already available in the public domain as part of Innovate UK's [transparency data](#)¹ on grants. As at 1st January 2021 Innovate UK has made grant awards to Cell and Gene Therapy Catapult of £262,163,284 with £196,091,989.35 of actual spend.

2. How much money has been spent on technology and digitisation? Alternatively, what have been the main areas of expenditure? What was the output of this spending?

The transparency data contains public descriptions of the various projects funded by Innovate UK. Innovate UK do not collect a breakdown of spend against technology areas, however for monitoring purposes grant holders provide financial information against the headings set out in the publicly available [finance form guidance](#)². For your convenience these are: Labour, Overheads, Materials, Capital Usage, Sub-Contract, Travel & Subsistence and Other.

The outputs are specific to each individual funded project and not collated so we are not able to provide an answer to this part of the question.

3. How much money was given to commercial technology partners of cell and gene therapy catapult? Who are the commercial partners, what was their function, and what technology or digital solution or services were provided and how did it help the sector?

Cell & Gene Therapy Catapult is an independent, private sector company and Innovate UK do not hold information on their commercial partners. Catapults are not funding bodies and are not able to use their core grant from Innovate UK to provide funding to other organisations. They may, in certain circumstances such as H2020 cascade funding projects, provide pass through funding on behalf of a funder but Innovate UK do not hold information on these activities.

4. How much money was spent with World Courier, DHL, ThermoFisher, Trakcel, Oxford Biomedica, and GSK? What was the purpose of the money and what was the result or outcome of such funding? What digital product and transformation was the result of such funding?

Innovate UK do not hold this information.

5. How many NHS hospitals, clinics or manufacturers in the UK or overseas are utilising innovations in technology produced by Trakcel or World Courier, and how much in funding was provided to these companies?

Innovate UK do not hold this information

As part of our duty to advise and assist under the FOIA, from the activity areas and organisations mentioned in your request you may find the following publicly available information about the Advanced Therapy Treatment Programme of interest and relevance [here](#)³.

If you have any queries regarding our response or you are unhappy with the outcome of your request and wish to seek an internal review of the decision, please contact:

Head of Information Governance

Email: foi@ukri.org or infogovernance@ukri.org

Please quote the reference number above in any future communications.

If you are still not content with the outcome of the internal review, you may apply to refer the matter to the Information Commissioner for a decision. Generally, the ICO cannot make a decision unless you have exhausted the review procedure provided by UKRI. The Information Commissioner can be contacted at: <http://www.ico.gov.uk/>


¹ <https://www.gov.uk/government/publications/innovate-uk-funded-projects>

² <https://www.gov.uk/government/publications/innovate-uk-completing-your-application-project-costs-guidance/partner-finance-form-guidance>

³ <https://www.theattnetwork.co.uk/>

If you wish to raise a complaint regarding the service you have received or the conduct of any UKRI staff in relation to your request, please see UKRI's complaints policy: <https://www.ukri.org/about-us/policies-and-standards/complaints-policy/>

Yours sincerely,


Information Governance
Information Rights Team
UK Research and Innovation
foi@ukri.org | dataprotection@ukri.org